Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis

2020 ◽  
Vol 31 (7) ◽  
pp. 606-612
Author(s):  
Husein Husein-ElAhmed
Keyword(s):  
Human Papillomavirus ◽  
Meta Analysis ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Control Group ◽  
Effect Estimate ◽  
Human Papillomavirus Vaccine ◽  
Eligibility Criteria ◽  
Transmitted Infection ◽  
Sexually Transmitted

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection worldwide and ano-genital warts (AGWs) are highly infectious. This virus is transmitted through sexual, anal, or oral contact as well as skin-to-skin contacts. Treatment for this condition has significant morbidity and it can be frustrating in certain cases. The HPV vaccination has been demonstrated as a promising strategy of secondary prevention in HPV-related diseases such as head and neck cancers, cervical diseases, and recurrent respiratory papillomatosis. Regarding AGWs, it is unclear whether vaccination can provide analogous clinical benefit. The aim of this work is to systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of AGWs. From October to December 2018, a systematic search for clinical trials was conducted in five databases: PubMed, MEDLINE, EMBASE, Cochrane, and clinicaltrials.gov using a combination of the following descriptors: ‘gardasil’ OR ‘cervarix’ OR ‘nine-valent’ OR ‘9-valent’ OR ‘vaccine’ AND ‘recurrence’ OR ‘relapse’ AND ‘hpv’ OR ‘papillomavirus’ AND ‘warts’ OR ‘condyloma.’ Data were synthetized and entered in the Review Manager software (RevMan 5.3.5) to perform the meta-analysis. The search yielded 824 potentially relevant studies. Two studies fulfilled the eligibility criteria involving 656 participants. The meta-analysis estimated the rate of recurrence of AGWs was similar between the vaccine group and the control group. The overall effect estimate was 1.02 (0.75–1.38). This is the first meta-analysis exploring the effect of HPV vaccine in preventing the relapse of AGWs. These results suggest that HPV vaccination does not provide secondary benefit in patients with previous AGWs. However, these results cannot be generalized due to the scarce number of RCTs currently available in the literature. The outcomes from future randomized controlled trials (RCTs) are warranted to further clarify the precise effect of the vaccine.

Human Papillomavirus, Genital Warts and Vaccination

2009 ◽  
Vol 2 (9) ◽  
pp. 522-529 ◽  
Author(s):  
Laura Pye
Keyword(s):  
Human Papillomavirus ◽  
Natural History ◽  
Clinical Presentation ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Condyloma Acuminata ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
History Of ◽  
The Uk

Genital warts (condyloma acuminata) are caused by the human papillomavirus (HPV) and are the most frequently diagnosed viral sexually transmitted infection in the UK. This article aims to provide an overview of the natural history of HPV, the clinical presentation and management of genital warts and an overview of the national HPV vaccination programme.

scholarly journals Sexually Transmitted Infections and Male Circumcision: A Systematic Review and Meta-Analysis

ISRN Urology ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-42 ◽  
Author(s):  
Robert S. Van Howe
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Sexually Transmitted Infections ◽  
Sexually Transmitted Infection ◽  
Positive Impact ◽  
Meta Analysis ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
General Populations ◽  
Simplex Virus

The claim that circumcision reduces the risk of sexually transmitted infections has been repeated so frequently that many believe it is true. A systematic review and meta-analyses were performed on studies of genital discharge syndrome versus genital ulcerative disease, genital discharge syndrome, nonspecific urethritis, gonorrhea, chlamydia, genital ulcerative disease, chancroid, syphilis, herpes simplex virus, human papillomavirus, and contracting a sexually transmitted infection of any type. Chlamydia, gonorrhea, genital herpes, and human papillomavirus are not significantly impacted by circumcision. Syphilis showed mixed results with studies of prevalence suggesting intact men were at great risk and studies of incidence suggesting the opposite. Intact men appear to be of greater risk for genital ulcerative disease while at lower risk for genital discharge syndrome, nonspecific urethritis, genital warts, and the overall risk of any sexually transmitted infection. In studies of general populations, there is no clear or consistent positive impact of circumcision on the risk of individual sexually transmitted infections. Consequently, the prevention of sexually transmitted infections cannot rationally be interpreted as a benefit of circumcision, and any policy of circumcision for the general population to prevent sexually transmitted infections is not supported by the evidence in the medical literature.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

Intention of college students to receive the human papillomavirus vaccine

2016 ◽  
Vol 116 (4) ◽  
pp. 342-355 ◽  
Author(s):  
Keith Richards
Keyword(s):  
College Students ◽  
Human Papillomavirus ◽  
Information Seeking ◽  
Hpv Vaccine ◽  
Human Papillomavirus Vaccine ◽  
Transmitted Infection ◽  
Content Type ◽  
Sexually Transmitted ◽  
The Usa ◽  
To Receive

Purpose – The purpose of this paper is to better understand what influences the intentions of college students to receive the human papillomavirus (HPV) vaccine. HPV is the most common sexually transmitted infection in the USA and cancers related to HPV are on the rise. Design/methodology/approach – A 2×2 experimental design was used to predict the intentions. Messages were created that manipulated the level of severity and vulnerability to determine which would increase intentions to receive the HPV vaccine. Each of the 278 participants viewed a message that contained one severity message (high or low) and one vulnerability message (high or low). Findings – Regression was used to determine that elements of the protection motivation theory such as vulnerability and fear, along with norms, and information seeking explained a significant portion of the variance in intent to be vaccinated (R2=0.40, F(4, 268)=44.47, p < 0.001). Norms had the most influence on intention (β=0.42, p < 0.001), next was vulnerability (β=0.21, p < 0.001) then fear (β=0.16, p=0.002), and finally information seeking (β=0.10, p=0.01). Originality/value – The current college age population did not have the opportunity to be vaccinated early and the recent (2011) recommendation that males get vaccinated makes this research valuable to those designing vaccination messages. The current study shows that norms were the most influential variable in regards to increasing intent to get vaccinated. This means that if the participant believed their friends would support or endorse their intent to get vaccinated they were more likely to say they would follow through and get vaccinated. This finding should be highlighted in any future campaign.

scholarly journals Preparations for implementing human papillomavirus vaccination should begin

2005 ◽  
Vol 10 (37) ◽  
Author(s):  
M Lehtinen
Keyword(s):  
Human Papillomavirus ◽  
World Health Organization ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccination ◽  
World Health ◽  
Human Papillomavirus Vaccination ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
National Programmes ◽  
Health Organization

At a World Health Organization meeting, the latest developments in human papillomavirus (HPV) vaccination were discussed. The leading theme that emerged was how to implement within national programmes the concept of vaccinating adolescents both against a common sexually transmitted infection

scholarly journals Sexual Health Variables and the Human Papillomavirus Vaccine

2009 ◽  
Vol 7 (2) ◽  
pp. 129-138
Author(s):  
Victoria Barry ◽  
Shannon B. Myers ◽  
Amy E. Sgrenci ◽  
Megan Lavery ◽  
Deirdra Frum ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Pap Smear ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
The United States ◽  
Human Papillomavirus Vaccine ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Status Seeking

Recent strides have been made in developing vaccines to prevent contraction of the Human Papillomavirus (HPV), which is currently the most prevalent sexually transmitted disease in the United States. This study looked to investigate seven sexually relevant variables hypothesized to be related to a young woman's choice to receive the Gardasil® vaccine in order to prevent HPV contraction via a cross sectional survey. In a sample of 77 undergraduate women, we investigated the relationship between receipt of Gardasil® and the following variables: knowledge regarding HPV, relationship status, seeking gynecological services, having received an abnormal PAP smear, sexual activity status, number of sexual partners, and concern about contracting HPV. Logistical regression analysis and independent groups t-test revealed that none of these factors were related to actual receipt of the HPV vaccine in this sample. These results suggest the need for more research regarding potential practical barriers to HPV vaccination.

Human Papillomavirus Infection and Prevention In The Adolescent

2020 ◽  
Author(s):  
Alexandria Richards ◽  
Joanna Stacey
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
Cervical Dysplasia ◽  
Vaccine Safety ◽  
Genital Warts ◽  
Hpv Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection

Human papillomavirus, or HPV, is a common sexually transmitted disease, most often acquired during the adolescence or the early 20s. It can be divided into oncogenic and nononcogenic serotypes. It is responsible for genital warts as well as pathologic diseases that can lead to genital cancers and cancers of the oropharyngeal tract in both males and females. The majority of adolescents who acquire HPV infections do not go on to develop cancer. New discoveries about the virus’ persistence and latency direct how we treat adolescents with HPV infections. Recommendations for prevention of HPV include use of the 9-valent vaccine against the most common oncogenic HPV serotypes. Screening should be delayed until the age of 21, with the exception of immunocompromised women. The HPV vaccination is safe and effective, and does not encourage sexual activity among adolescents. Both boys and girls should be vaccinated against HPV at 11 to 12 years of age but may receive the vaccination as early as 9 or as late as 21 (males) or 26 (females) years of age. The vaccine may now also be given in only two doses if the series was started before the age of 15. Follow-up studies in the years after the vaccine’s introduction have shown large decreases in HPV infection rates. This review contains 7 figures, 7 tables and 63 references Key Words: Oncogenic subtype, Oropharyngeal cancer, Infection persistence, Immune tolerance, Cervical dysplasia, Genital warts, 9-valent vaccine, Vaccine safety  

Anal and oral human papillomavirus infection in men who have sex with men: implications for risk-targeted vaccination

2020 ◽  
Vol 15 (18) ◽  
pp. 1713-1722
Author(s):  
Maria Gabriella Donà ◽  
Francesca Rollo ◽  
Alessandra Latini ◽  
Maria Benevolo ◽  
Barbara Pichi ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Linear Array ◽  
Hpv Vaccination ◽  
Risk Groups ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection ◽  
Significant Burden ◽  
Sex With Men

Aim: Men who have sex with men (MSM) harbor a significant burden of human papillomavirus (HPV)-related diseases that could be prevented by vaccination. Materials & methods: Prevalence of HPVs targeted by the quadrivalent (4vHPV) and nonavalent vaccines (9vHPV) was assessed in anal (n = 443) and oral (n = 193) specimens of immunocompetent, sexually active MSM, using the Linear Array. Results: Of the anal samples, 34.1 and 46.0% were positive for at least one genotype of those covered by the 4vHPV and 9vHPV, respectively. At least one of the HPVs targeted by the 9vHPV was detected in 5.7% of the oral specimens. Conclusion: The majority of the subjects were not currently infected by HPV-16 and other vaccine-preventable HPVs. Universal HPV vaccination should be strongly promoted in order to achieve protection for all risk groups. In the meanwhile, vaccination should be offered to sexually active adult MSM attendees of sexually transmitted infection centers, although its potential benefit for these subjects needs to be further investigated.

Mandating a Human Papillomavirus Vaccine: An Investigation into Whether Such Legislation is Constitutional and Prudent

2008 ◽  
Vol 34 (1) ◽  
pp. 65-84 ◽  
Author(s):  
Tracy Solomon Dowling
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Transmitted Disease ◽  
Genital Warts ◽  
Cervical Cancer Prevention ◽  
Health Concern ◽  
Human Papillomavirus Vaccine ◽  
Public Health Concern ◽  
Sexually Transmitted ◽  
Papillomavirus Vaccine

Merck’s recently released vaccine, Gardasil, may revolutionize cervical cancer prevention. With the rate of detected cervical cancer cases and associated deaths rising rapidly, cervical cancer is a major public health concern. Infection with the human papillomavirus, a sexually transmitted disease, is a necessary cause of cervical cancer. Gardasil protects against two specific “high risk” strains of HPV, associated with about 70% of cervical cancer cases, and blocks infection by two other strains of HPV, responsible for 90% of genital warts cases. Proponents of Gardasil believe that vaccination of women between the ages of 12 and 26 can slow the spread of cervical cancer by eradicating the two major HPV strands associated with the cancer’s development.

scholarly journals Epidemiology of genital warts in the British population: implications for HPV vaccination programmes

2019 ◽  
Vol 95 (5) ◽  
pp. 386-390 ◽  
Author(s):  
Pam Sonnenberg ◽  
Clare Tanton ◽  
David Mesher ◽  
Eleanor King ◽  
Simon Beddows ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Genital Warts ◽  
Sample Survey ◽  
Similar Proportion ◽  
Computer Assisted ◽  
Transmitted Infection ◽  
Men And Women ◽  
Sexually Transmitted ◽  
Sex With Men ◽  
Sexual Health Clinics

ObjectivesTo estimate the prevalence of, and describe risk factors for, genital warts (GWs) in the British population, following the introduction of the bivalent (human papillomavirus (HPV)-16/18) vaccination programme in girls, and prior to the switch to quadrivalent (HPV-6/11/16/18) vaccine (offering direct protection against GWs) and compare this with GW diagnoses in the prevaccination era.MethodsNatsal-3, a probability sample survey in Britain, conducted in 2010–2012, interviewed 9902 men and women aged 16–44. Natsal-2, conducted in 1999–2001, surveyed 11 161 men and women aged 16–44. Both surveys collected data on sexual behaviour and sexually transmitted infection diagnoses using computer-assisted interview methods.ResultsIn Natsal-3, 3.8% and 4.6% of sexually experienced men and women reported ever having a diagnosis of GWs, with 1.3% of men and 1.7% of woman reporting a GWs diagnosis in the past 5 years. GWs were strongly associated with increasing partner numbers and condomless sex. Diagnoses were more frequent in men who have sex with men (MSM) (11.6% ever, 3.3% past 5 years) and in women reporting sex with women (10.8% ever, 3.6% past 5 years). In the age group who were eligible for vaccination at the time of Natsal-3 (16–20 years), a similar proportion of same-aged women reported a history of GWs in Natsal-2 (1.9%, 1.1–3.4) and Natsal-3 (2.6%, 1.5–4.4).ConclusionsThese data provide essential parameters for mathematical models that inform cost-effectiveness analyses of HPV vaccination programmes. There was no evidence of population protection against GWs conferred by the bivalent vaccine. Even with vaccination of adolescent boys, vaccination should be offered to MSM attending sexual health clinics.

Sign in / Sign up

Export Citation Format

Share Document